Cyprotex extends ties with Pfizer

Cyprotex, the pharmaceuticals company specialising in the adverse effects of chemicals on living organisms, has signed a collaborative research agreement with US pharmaceuticals giant Pfizer.

The two parties will evaluate, further develop, and improve several of Cyprotex's proprietary offerings in the area of predictive toxicology.

The deal extends over an eighteen month period and is split into two stages with the second stage being dependent on certain milestones being achieved.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

"This collaborative research is beneficial for both companies and allows Cyprotex to remain at the forefront of new approaches in toxicology prediction. Predicting drug-induced toxicity is a challenging field, and we are making significant advances by combining our knowledge with that of our partners and clients," said Dr Anthony Baxter, Cyprotex's Chief Executive Officer.